Indeed, a literature search revealed only two publications: an immunohistochemistry study that reported no IGFBP2 in medulloblastoma, and a gene expression study finding significant-up-regulation of IGFBP2 in medulloblastoma and a link to poor prognosis [10, 43]. This evidence concerns the gene IGFBP2 and medulloblastoma.